Phase 2 N=86 Effectiveness of Lofexidine to Prevent Stress-Related Opiate Relapse During Naltrexone Treatment - 1
Opioid-Related Disorders
Primary: SOWS: the Subjective Opiate Withdrawal Scale — 11.5; 12.5 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=524 Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents
Prevention of Meningococcal Disease
Primary: Percentages of Subjects With N.Meningitidis Human Serum Bactericidal Activity (hSBA) Titers≥ 1:4, After One Dose of Either MenACWY-CRM Vaccine, With Adjuvant or Without…
Phase 2 N=58 Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer
Primary: Tumor Response Duration — 3.9; 24.1 months
Phase 2 N=28 BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer
Breast Neoplasms
Primary: Percentage of Progression Free Participants After 16 Weeks of Treatment — 28.57; 0.00; 25.00 Percentage of participants
Phase 2 N=338 A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)
Functional Dyspepsia
Primary: Rate of Complete Dyspepsia Symptom Relief — 22.4; 29.3; 27.0; 17.9 Percentage of Participants
Phase 2 N=45 A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis
Cutaneous Leishmaniasis
Primary: Date of Clinical Cure — 2; 2; 15; 10 participants
Phase 2 N=294 A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia
Neuralgia, Postherpetic
Primary: Change From Baseline in the Average Pain Intensity Score at Week 12 — 6.13; 6.04; 6.05; -1.42 Score on a scale
Phase 2 N=79 Study Evaluating Bapineuzumab In Alzheimer Disease Subjects
Alzheimer Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 16; 22; 28; 1 participants
Phase 2 N=107 Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)
Acne Vulgaris
Primary: Proportion of Patients With Success According to the Dichotomized IGA Scale Based on Facial Assessments 12 Weeks After the First Treatment. Success is Defined as an…
Phase 2 N=20 Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy
Pancreatic Cancer
Primary: Overall Survival Rate at 6 Months — 58 percentage of participants
Phase 2 N=35 Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma
Melanoma
Primary: Response Rate (RR) — 1; 2; 1; 8 participants
Phase 2 N=608 Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
Overweight · Obesity
Primary: Least Squares (LS) Mean Percent Change in Body Weight From Baseline to Week 28 - Evaluable Population — -2.01; -5.47; -5.83; -6.85 Percentage change in kg — p=<0.0001
Phase 2 N=60 Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours
Neoplasms
Primary: Objective Response (OR) — 1 Participants with OR
Phase 2 N=28 The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Forced Expiratory Volume in One Second (FEV1), Peak Effect Within 0 - 24 Hours Post-dose — 1.67; 1.73; 1.64 L
Phase 2 N=74 LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib
Carcinoma, Non-Small-Cell Lung
Primary: Phase I Step: Safety of BIBW 2992 Assessed Based on Incidence of Dose Limiting Toxicity (DLT) and Incidence & Intensity of Adverse Events According to CTCAE — 3; 3; 6; 3…